Sign In
Buy MACK
$15.13
+0 (+0%)
At Close: Aug 19, 2024
Hedge Funds Are Selling Merrimack Pharmaceuticals Inc (MACK)
12:44am, Monday, 23'rd Dec 2019
Is Merrimack Pharmaceuticals Inc (NASDAQ:MACK) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Arde
Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan
02:15pm, Tuesday, 03'rd Dec 2019
Merrimack Pharmaceuticals, Inc. (MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has adopted a Section 382 net operating loss rights plan (t
Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend
01:45pm, Tuesday, 03'rd Dec 2019
Merrimack Pharmaceuticals, Inc. (MACK) today announced that it received a $5 million milestone payment from Ipsen, triggered by Ipsen’s decision to progress the ongoing multi-part clinical trial eva
The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
12:00am, Friday, 22'nd Nov 2019Western Standard, LLC Buys Extended Stay America Inc, Celgene Corp, Meta Financial Group Inc, ...
12:00am, Thursday, 14'th Nov 2019Proxy fights reach 'frightening' level in life sciences, other industries, top attorney says
10:04am, Monday, 28'th Oct 2019
Attorney and proxy fight expert Kai Liekefett estimated that upwards of 10 percent of public companies have faced activist investor challenges so far this year.
